different glp-1 agonists Free Comparison Chart: and GIP/GLP-1 Receptor for Type 2 Diabetes 🔗 Link in bio #FOAMed #Type2Diabetes #GLP1 Understanding GLP-1 receptor agonists and

The dual GIP/GLP-1 receptor agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects

A comprehensive program of nutritional and lifestyle counseling is critical to maximize overall efficacy and improve cost-effectiveness of GLP-1s for obesity.

In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need

Retatrutide vs Semaglutide: Evidence-based comparison of the investigational triple GIP/GLP-1/glucagon agonist versus the FDA-approved GLP-1 agonist

A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D